The size of the North America In-Situ Hybridization Market is estimated at USD 185.81 million in 2023. This value is estimated to be growing at a CAGR of 5.8% to reach USD 246.32 million by 2028.
The deployment of ISH technology is expected to grow in the coming years as the demand for molecular diagnostic tools increases, which is expected to boost the ISH market in the North American region. Also, the rising use of ISH is being fuelled by the rise in chronic diseases and a demand for quick diagnostic techniques.
North America witnessed a significant rise in cancer across the region, influencing the market growth. However, the other factors, such as growing awareness about companion diagnostics tests in IAH, the proliferation of genetic disorders across the region, are expected to propel the market growth.
On the other hand, the major players in the region are conducting research and developing activities on human diseases to identify genetic disorders that are positively driving market growth. Cytogenetic tests like ISH, which aid in integrating IHC and DNA FISH, are among the in-situ toolsets that enable researchers to discover, develop, and use new-generation diagnostic methods. Direct imaging of gene expression in situ at the RNA level offers a unique view of how cancer cells interact with the tumor microenvironment as the disease progresses.
According to GLOBOCAN, in the United States, roughly 1,806,590 new cancer cases will be identified, with 606,520 people dying from the disease. In 2040, the number of people diagnosed with cancer could reach 2.9 million, with a death rate of 1.6 million. In addition, according to McMaster University research, hereditary illnesses are on the rise. For example, hemophilia frequency in Canada has tripled to 1,217,357 people, up from 450,000 in prior estimates. Canada and the United States are the countries most affected. This rate is anticipated to have an impact on the market for in-situ hybridization.
The development of therapeutic applications has significantly contributed to the market’s overall expansion. A rise in government activities resulting from a significant number of cases is also influencing the market positively. In addition, increasing healthcare costs due to higher disposable income is a positive sign of the North American ISH market’s growth rate.
However, there is a scarcity of qualified, well-trained, and technically savvy laboratory personnel who can perform ISH-based diagnostics, hindering its wider use, particularly in emerging markets. Understanding the molecular information of a chromosome or gene is required to execute an ISH-based test. Another barrier to market expansion is a reluctance to move from manual to automated activities. Many vendors find it difficult, if not impossible, to make the transition from manual or old procedures to IT alternatives.
This research report on North America in situ hybridization market has been segmented and sub-segmented into the following categories:
By Technique:
By Application:
By End User:
By Type:
By Product:
By Country:
Geographically, North America dominated the global In Situ Hybridization market with the largest market share in 2020. The market growth is driven by rising government initiatives, increasing biomedical research, rising cancer prevalence, and increasing desire for companion diagnostics and tailored medication are all driving the in-situ hybridization market in the United States. Oxford Gene Technology has gained FDA approval for eight Cytocell FISH probes that can be used to diagnose acute myeloid leukemia and myelodysplastic syndromes. Because North America is home to many clinical research laboratories and institutes, new products development is projected to be prioritized.
The U.S. dominated the North American In situ Hybridization market, and it is likely to continue its domination during the forecast period. The market growth is attributed to the increased incidence of cancer, rising healthcare expenditure, and availability of advanced healthcare facilities. According to the National Cancer Institute, the national spending on cancer care in the United States was around USD 125 billion in 2010 and is expected to reach USD 156 billion in 2020.
One of the newest technologies on the market is the Silver In Situ Hybridization (SISH) assay technique, a kind of Chromogenic In Situ Hybridization (CISH). The “INFORM HER2 SISH DNA Probe Assay” was introduced by Ventana Medical System solely in the United States to detect the HER2 gene in breast cancer patients. This is due to the availability of research funds and government activities to create novel diagnostic techniques in this region.
KEY MARKET PLAYERS:
A few of the notable companies operating in North America in situ hybridization market analyzed in this report are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.).
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region